<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>
<body><p><strong>12. Hepatic Encephalopathy</strong></p><p>This condition is a complication of either acute or chronic liver disease. It presents with disordered central nervous system function, due to inability of the liver to detoxify ammonia and other chemicals.</p><p>&nbsp;</p><p><strong>CAUSES</strong></p><ul><li>Viral hepatitis</li><li>Alcoholic hepatitis</li><li>Cirrhosis of the liver</li><li>Hepatocellular carcinoma</li><li>Drugs&nbsp; e.g. halothane, isoniazid, paracetamol overdose, herbal preparations</li><li>Fatty liver of pregnancy</li><li>Precipitating factors in a patient with pre-existing liver disease:<ul><li>Fever</li><li>Hypotension</li><li>Infection</li><li>Fluid and electrolyte imbalance (excessive use of loop diuretics)</li><li>Sedatives</li><li>Increased gastrointestinal tract (GIT) protein load e.g. heavy GIT bleeding, alcoholic binge</li></ul></li></ul><p>&nbsp;</p><p><strong>SYMPTOMS</strong></p><ul><li>Jaundice</li><li>Confusion</li><li>Disturbed consciousness which progresses as follows: disorder of sleep, hypersomnia and inversion of sleep rhythm, apathy and eventually coma</li><li>Personality changes</li></ul><p>&nbsp;</p><p><strong>SIGNS</strong></p><ul><li>Cyanosis</li><li>Fetor hepaticus</li><li>Signs of chronic liver disease</li><li>Neurological abnormalities:<ul><li>Speech impairment</li><li>Asterixis (a flapping tremor) indicates pre-coma and strongly supports the diagnosis of encephalopathy</li><li>Inability to draw or construct objects e.g. a 5-pointed star</li><li>Incoordination</li><li>Lethargy</li><li>Encephalopathy<ul><li>Grade 1: Mild confusion, irritable, tremor, restless</li><li>Grade 2: Lethargic responses, decreased inhibitions, disorientation, agitation, asterixis</li><li>Grade 3: Stuporous but arousable, aggressive bursts, inarticulate speech and marked confusion</li><li>Grade 4: Coma</li></ul></li></ul></li></ul><p>&nbsp;</p><p><strong>INVESTIGATIONS</strong></p><ul><li>FBC</li><li>Blood glucose</li><li>Liver function tests</li><li>Blood urea and electrolytes</li><li>Hepatitis B-surface-Antigen</li><li>Hepatitis C screen</li><li>Prothrombin time, INR</li><li>Infection screen (blood culture, urine RE, chest X-Ray, diagnostic ascitic tap)</li></ul><p>&nbsp;</p><p><strong>TREATMENT</strong></p><p><strong>Treatment objectives</strong></p><ul><li>To identify and correct precipitating factors promptly</li><li>To treat underlying cause of liver disease</li></ul><p>&nbsp;</p><p><strong>Non-pharmacological treatment</strong></p><ul><li>Place in the coma position if unconscious</li><li>Maintain fluid and electrolyte balance (avoid dehydration and</li><li>electrolyte abnormalities such as hypokalaemia)</li><li>Monitor temperature, pulse and respiratory rate, blood pressure, pupils, urine output and blood glucose regularly</li><li>Avoid alcohol, paracetamol and other hepatotoxic agents</li><li>Avoid sedatives such as benzodiazepines and drugs that impair the coagulation system</li><li>Patients should N0T have their protein intake restricted</li><li>Maintain an adequate protein intake of 1.2-1.5 g/kg per day</li><li>Encourage intake of high carbohydrate diet by mouth or NG tube</li></ul><p>&nbsp;</p><p><strong>Pharmacological treatment</strong></p><ol><li><strong>Measures to correct hydration status and nutrition</strong></li></ol><p>Evidence Rating: [A]</p><p><strong><u>Adults</u></strong></p><p>• &nbsp;Dextrose saline (5-10% dextrose in 0.9% saline), IV, 500 ml 8 hourly (according to requirements)</p><p><strong>And</strong></p><p>• &nbsp;High potency Vitamin B, IV, (formulated as two separate vials) 0ne pair of vials daily (added to glucose IV solution)</p><p><strong><u>Children</u></strong></p><p>• &nbsp;Dextrose saline (4.3% in 0.18% saline), IV,</p><p><strong>And</strong></p><p>• &nbsp;High potency Vitamin B, IV, (formulated as two separate vials)</p><p><strong>B. Measures to lower blood ammonia concentration</strong></p><p><strong>1st Line Treatment</strong></p><p>Evidence Rating: [A]</p><p>• &nbsp;Lactulose, oral,</p><p><strong><u>Adults</u></strong></p><p>&nbsp; Start with 30-45 ml (20-30 g), 6-12 hourly</p><p>(Review dose to maintain 2-3 semi-solid stools per day)</p><p><strong><u>Children</u> and <u>Adolescents</u></strong></p><p>&nbsp; Start with 5-20 ml 6-12 hourly</p><p>(Review dose to maintain 2-3 semi-solid stools per day)</p><p><strong><u>Neonates</u></strong></p><p>Start with 0.5-5 ml 6-12 hourly</p><p>(Review dose to maintain 2-3 semi-solid stools per day)</p><p><strong>Or</strong></p><p>• &nbsp;Lactulose, rectal,</p><p>300 ml diluted in 700 ml water (via rectal balloon catheter) 4-6 hour- ly, retain in the rectum for 30-60 minutes. (Review dose to maintain 2-3 semi-solid stools per day)</p><p><strong>And</strong></p><p>• &nbsp;Metronidazole, oral,</p><p><strong><u>Adults</u></strong></p><p>&nbsp; 400 mg 8 hourly</p><p><strong><u>Children</u></strong></p><p>&nbsp; &nbsp;15 mg/kg 12 hourly</p><p><strong><u>Neonates</u></strong></p><p>&gt;2 kg;&nbsp; &nbsp;&nbsp; 15 mg/kg 12 hourly</p><p>1-2 kg; 7.5 mg/kg 12 hourly</p><p><strong>2nd Line Treatment&nbsp;</strong></p><p>Evidence Rating: [A]</p><p>• &nbsp;Rifaximin, oral,</p><p><strong><u>Adults</u></strong></p><p>&nbsp; 550 mg 12 hourly</p><p><strong><u>Children</u></strong></p><p>&gt;12 years;&nbsp; 200 mg 8 hourly</p><p>&lt; 12 years; not recommended</p><p>&nbsp;</p><p><strong>C.&nbsp; Hepatic encephalopathy associated with active bleeding (INR &gt; 1.5 or platelet count &lt; 50 x 109 /L)</strong></p><p><strong><u>Adults and Children (liaise with Haematology)</u></strong></p><p>• &nbsp;Fresh frozen plasma, IV, (for INR &gt;1.5)</p><p><strong>Or</strong></p><p>• &nbsp;Platelet concentrate, IV, (platelet count &lt; 50 x 109 /L)</p><p><strong>D.&nbsp; Antibiotic prophylaxis in Hepatic encephalopathy (associated with cirrhosis and upper gastro-intestinal haemorrhage)</strong></p><p>Patients in whom oral administration is not possible,</p><p>Evidence Rating: [A]</p><p>• &nbsp;Ciprofloxacin, IV,</p><p><strong><u>Adults</u></strong></p><p>&nbsp; 400 mg 8-12 hourly (administered over 60 minutes)</p><p><strong>Or</strong></p><p>• &nbsp;Ceftriaxone, IV, 1 g daily for 7 days</p><p><strong>Or</strong></p><p>• &nbsp;Ciprofloxacin, oral, 500 mg 12 hourly</p><p><strong>Or</strong></p><p>• &nbsp;Norfloxacin, oral, 400 mg 12 hourly for 7 days</p><p>&nbsp;</p><p><strong>E.&nbsp; Hepatic encephalopathy precipitated by bacterial infection</strong></p><p><strong>Note 2-4</strong></p><p><strong>A diagnosis of SBP is established if the neutrophil count in the ascitic fluid is &gt;250 cells/mL, culture results positive and surgically treatable causes are excluded. Patients with suspected SBP should be started on empiric antibiotics immediately after ascitic fluid is obtained pending results:</strong></p><p>Evidence Rating: [A]&nbsp;</p><p><strong>1st Line treatment</strong></p><p>• &nbsp;Ciprofloxacin, IV, 400 mg 8-12 hourly for 2 days (to be administered over 60 minutes)</p><p><strong>&nbsp; Then</strong></p><p>• &nbsp;Ciprofloxacin, oral, 500 mg 12 hourly for 5 days</p><p>&nbsp;</p><p><strong>Note 2-5</strong></p><p><strong>Avoid in patients with prior fluoroquinolone therapy as SBP prophylaxis or his- tory of resistance.</strong></p><p><strong>2nd Line treatment</strong></p><p>•Cefotaxime, IV, 2 g 8 hourly for 7 days Or</p><p>•Ceftriaxone, IV, 2 g daily for 7 days</p><p>&nbsp;</p><p><strong>REFERRAL CRITERIA</strong></p><p>Refer patients if the condition does not improve. All children with hepatic encephalopathy must be referred to a specialist.</p>
</body>
</html>
